Bioceltix S.A. (XI3.F)
- Previous Close
22.85 - Open
24.25 - Bid 24.45 x --
- Ask 29.90 x --
- Day's Range
22.80 - 24.45 - 52 Week Range
11.74 - 25.05 - Volume
10 - Avg. Volume
0 - Market Cap (intraday)
131.772M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.88 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
bioceltix.comRecent News: XI3.F
View MorePerformance Overview: XI3.F
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XI3.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XI3.F
View MoreValuation Measures
Market Cap
132.29M
Enterprise Value
123.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
11.65
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.11%
Return on Equity (ttm)
-56.22%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.65M
Diluted EPS (ttm)
-0.88
Balance Sheet and Cash Flow
Total Cash (mrq)
38.2M
Total Debt/Equity (mrq)
2.29%
Levered Free Cash Flow (ttm)
-12.78M